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Abstract
Background: There is increasing global acceptance that viscous soluble fibers lower serum LDL cholesterol (LDL-C),
but most evidence for this comes from studies in Caucasians. To see if oat b-glucan lowers LDL-C in Caucasians
and non-Caucasians we conducted a post-hoc analysis of the results of a randomized, controlled, double-blind,
multi-center clinical trial whose primary aim was to determine if molecular-weight (MW) influenced the LDL-C-
lowering effect of oat b-glucan.
Results: Caucasian and non-Caucasian subjects with LDL-C-C ≥ 3.0 and ≤ 5.0 mmol/L (n = 786 screened, n = 400
ineligible, n = 19 refused, n = 367 randomized, n = 345 completed, n = 1 excluded for missing ethnicity) were
randomly assigned to consume cereal containing wheat-fiber (Control, n = 74:13 Caucasian:non-Caucasian) or 3 g
high-MW (3H, 2,250,000 g/mol, n = 67:19), 4 g medium-MW (4 M, 850,000 g/mol, n = 50:17), 3 g medium-MW (3M,
530,000 g/mol, n = 54:9) or 4 g low-MW (4 L, 210,000 g/mol, n = 51:12) oat b-glucan daily for 4 weeks. LDL-C after
4 weeks was influenced by baseline LDL-C (p < 0.001) and treatment (p = 0.003), but not ethnicity (p = 0.74). In all
subjects, compared to control, 3 H, 4 M and 3 M reduced LDL-C significantly by 4.8 to 6.5%, but 4 L had no effect.
Compared to control, the bioactive oat b-glucan treatments (3H, 4M and 3M) reduced LDL-C by a combined mean
(95% CI) of 0.18 (0.06, 0.31) mmol/L (4.8%, n = 171, p = 0.004) in Caucasians, a value not significantly different from
the 0.37 (0.09, 0.65) mmol/L (10.3%, n = 45, p = 0.008) reduction in non-Caucasians.
Conclusion: We conclude that oat b-glucan reduces LDL-C in both Caucasians and non-Caucasians; there was
insufficient power to determine if the magnitude of LDL-C-lowering differed by ethnicity.
Trial Registration: ClinicalTrials.gov: NCT00981981
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Introduction
Coronary heart disease (CHD) is a leading cause of mor-
bidity and mortality globally [1,2]. It is well established
that reducing serum low-density-lipoprotein-cholesterol
(LDL-C) reduces risk for CHD [3]. Lifestyle modifications
to reduce CHD risk include increased consumption of
viscous soluble dietary fiber [4]. Oats are a good source
of soluble fiber, the major component of which is (1®3)
(1®4)-b-D-glucan, or b-glucan. Many, but not all studies
have shown that oat-containing food products reduce
serum LDL-C [5]. We showed that the LDL-C-lowering
effect of oat b-glucan depended on its viscosity [6] which,
in turn, depends on molecular weight (MW) and solubi-
lity [7]; 3-4 g/d of oat b-glucan with MW ranging from
5.3 × 105 to 2.2 × 106 g/mol significantly reduced LDL-C
by 4.8 to 6.5%, but 4 g/d of oat b-glucan with MW 2.1 ×
105 g/mol had no significant effect [6]. Since there is evi-
dence that the prevalence of blood lipid abnormalities
and other CHD risk factors varies in different ethnic
groups [8] and that the LDL-C-lowering effect of statins
differs by ethnicity [9,10], we examined our data to see if
the effect of oat b-glucan on LDL-C varied by ethnicity.
Methods
The methodology and main results of the trial have
been reported elsewhere [6]. Briefly, we conducted a
double-blind, randomized, parallel design, controlled
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clinical trial at 2 contract-research-organizations and 3
university nutrition research centers. Participants were
healthy men and women aged 35 to 70 yr with body
mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m2 and fasting
serum LDL-C ≥ 3.0 and ≤5.0 mmol/L; 786 subjects were
screened, 400 did not meet the inclusion criteria,
19 declined to participate, 367 were randomly assigned
to one of the 5 treatments and 22 discontinued treat-
ment before the end of the trial. Written informed con-
sent was obtained from all subjects. The protocol
was approved by the ethics review committee at each
participating institution. The trial was registered at
http://www.clinicaltrials.gov with identifier number
NCT00981981.
After eligibility had been determined subjects, stratified
by center and by LDL-C (stratum; low, 3.0 ≤ LDL-C ≤ 3.8
mmol/L; or high, 3.8 < LDL-C ≤ 5.0 mmol/L), were ran-
domly assigned to receive a ready-to-eat wheat bran cereal
(Control), or oat cereal providing a total of 3 g High-MW
(3 H, MW = 22.5 × 105 g/mol), 4 g Medium-MW (4 M,
MW = 8.5 × 105 g/mol), 3 g Medium-MW (3 M, MW =
5.3 × 105 g/mol) or 4 g Low-MW (4 L, MW = 2.1 × 105 g/
mol) oat b-glucan per day for 4 weeks. Cereals were
packed into air-tight foil sachets each containing half the
daily dose (10-14 g) and labelled with a code. After the
baseline blood sample, subjects were given a 1-week sup-
ply (14 sachets) of their assigned cereal and instructed to
consume 2 sachets daily, one with breakfast and one with
another meal or snack. Otherwise, subjects maintained
their usual diets and other lifestyle habits throughout the
study. The daily dose of cereals contained 234-339 kJ, 3-4
g protein, 1 g fat, 9-13 g carbohydrate and 6-8 g total fiber
[6]. Fasting blood was obtained weekly for analysis of total
and HDL cholesterol, triglycerides and calculated LDL-C.
Here we report the results for LDL-C in subjects based
on their ethnicity. Ethnicity was determined based on the
subjects’ own classification of themselves as Caucasian,
Black, Aboriginal, South Asian, Arab/West Asian, Filipino,
South East Asian, Hispanic, Chinese, Japanese, Korean or
other. Since the number of subjects in each non-Caucasian
category was too small for meaningful comparisons, for
the purposes of this analysis, subjects were classified as
either Caucasian or non-Caucasian.
Statistical analyses were performed using SAS (SAS 9.2,
XP-Pro, 2002-2008, SAS Institute, Inc., Cary, NC) on an
intent-to-treat basis using all available data from the 366
subjects randomly assigned to treatments and whose eth-
nicity could be identified (one of the 367 randomized
subjects was excluded for missing data on ethnicity). For
all 5 treatments, the main effects of treatment and ethni-
city and the treatment × ethnicity interaction on week 4
LDL-C was examined using analysis of covariance
(ANCOVA), controlling for baseline LDL-C and stratum;
the effects of sex, center, age, waist circumference and
BMI were tested but not included in the final model
because they had no significant effect (P > 0.1). Post hoc
testing was performed after demonstration of significant
heterogeneity by ANCOVA using Fisher’s LSD. The cri-
terion for declaring a statistically significant difference
was 2-tailed p < 0.05.
Results
The 296 Caucasian participants were older than the 70
non-Caucasians but were similar in sex, BMI and blood
lipids at baseline (Table 1). The total number (% non-
Caucasian), respectively, assigned to the 5 treatments
were: Control, 87 (15%); 3 H, 86 (22%), 4 M, 67 (25%);
3 M, 63 (14%), and 4 L 63 (19%) (p = 0.39). For most, but
not all, treatments, LDL-C tended to respond within 1-2
weeks of starting treatment and remain stable over the
last 2 weeks of the study (Figure 1). The results for
ANCOVA for LDL-C at week 4 showed significant effects
of baseline LDL-C (p < 0.001), stratum (p < 0.001) and
treatment (p = 0.003) but no significant effect of ethnicity
(p = 0.74) and no treatment × ethnicity interaction (p =
0.34). The latter indicates that the effects of the 5 treat-
ments on LDL-C did not differ significantly in Cauca-
sians vs non-Caucasians. Compared to Control, 3 H and
4 M reduced LDL-C significantly in Caucasians and 3 H,
3 M and 4 M reduced LDL-C significantly in non-Cauca-
sians (Figure 2). 4 L had no effect in either group. When
the results of the bioactive treatments (3 H, 4 M and 3
M) were pooled and compared to control, bioactive oat
b-glucan reduced LDL-C by a mean (95% CI) of 0.18
(0.06, 0.31) mmol/L (4.8%, p = 0.004) in Caucasians and
by 0.37 (0.09, 0.65) mmol/L (10.3%, p = 0.008) in non-
Caucasians; the difference between Caucasians and non-
Caucasians was not significant (p = 0.24).
Discussion
There is concern that the burden of chronic diseases is
neglected globally especially in low- and middle-income
countries [11]. Serum cholesterol, a marker of CHD
risk, has fallen over the last 30 years in high-income
Table 1 Characteristics of Caucasian and Non-Caucasian
subjects at baseline
Caucasian Non-Caucasian
n (male:female) 131:165 30:40 ns
Mean SD Mean SD p
Age (yr) 53.5 9.1 47.0 7.9 < 0.001
Body Mass Index (kg/m2) 27.5 4.2 27.5 4.3 ns
Waist circumference (cm) 93.3 21.1 90.8 12.2 ns
Total cholesterol (mmol/L) 5.99 0.72 5.77 0.77 ns
Triglycerides (mmol/L) 1.54 0.84 1.58 0.93 ns
HDL cholesterol 1.49 0.41 1.38 0.40 ns
LDL cholesterol 3.78 0.68 3.64 0.82 ns
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countries but has not changed significantly or even risen
in low- and middle-income countries [12]. To tackle the
burden of chronic disease a combination of strategies
may be used to promote healthy lifestyles [13]. It was
suggested that private-sector initiatives (such as high-
fiber breakfast-cereals) may be useful but more evidence
on their effectiveness is needed [13]. In this context,
there is increasing acceptance that viscous soluble fiber
lower serum cholesterol, with claims allowed in Malay-
sia for products containing oat b-glucan [14] and Japan
for products containing psyllium [15]. However, the evi-
dence for these effects comes largely from studies in
Caucasians. Thus, our results showing that oat b-glucan
lowered LDL-C in non-Caucasians may be helpful to
support global efforts to reduce CHD risk.
Since our study was not designed to compare the LDL-
C-lowering effect of oat b-glucan in different ethnic
groups, the results should be interpreted with caution.
Also, we pooled non-Caucasian ethnic groups amongst
whom differences may exist. Nevertheless, with 19% of
subjects being non-Caucasian, few, if any studies to date
on the cholesterol-lowering effects of oat b-glucan
include a population as large and diverse as ours. Bioac-
tive oat b-glucan tended to lower LDL-C more in non-
Caucasians than Caucasians (0.37 vs 0.18 mmol/L; or
10.3 vs 4.8%), but the difference was not statistically sig-
nificant. However, the study only had 34% power to
detect a significant difference between Caucasians and
non-Caucasians and, thus, was underpowered. Neverthe-
less, our results are consistent with the tendency for 3 g
oat b-glucan in a ready-to-eat cereal to reduce LDL-C
more in Hispanic Americans [16] than in predominantly
(86%) Caucasian subjects [17], 7.5 vs 4.4% relative to con-
trol. Therefore, this effect may warrant further study.
Conclusion
We conclude that oat b-glucan reduces LDL-C in Cau-
casians and non-Caucasians, but there was insufficient
Figure 1 Time course of unadjusted percent changes from
baseline of LDL-C in Caucasian (C) and non-Caucasian (N)
subjects randomly assigned to consume the control cereal
(Cont, C:N n = 74:13), or cereals containing 4 g low-MW oat b-
glucan (4 L, C:N n = 51:12), 3 g medium-MW oat b-glucan (3
M, C:N n = 54:9), 4 g medium-MW oat b-glucan (4 M, C:N n =
50:17) or 3 g high-MW oat b-glucan (3 H, C:N n = 67:19) daily
for 4 weeks. Values represent means ± SEM.
Figure 2 Difference in LDL-C, adjusted for baseline, in Caucasian (C, filled bars) and non-Caucasian (N, open bars) subjects after 4
weeks on cereals containing 4 g low-MW oat b-glucan (4 L, C:N n = 51:12), 3 g medium-MW oat b-glucan (3 M, C:N n = 54:9), 4 g
medium-MW oat b-glucan (4 M, C:N n = 50:17) or 3 g high-MW oat b-glucan (3 H, C:N n = 67:19) daily versus mean adjusted-LDL-C
after 4 weeks on Control in the same ethnic group. Values are means ± 95% CI.
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power to determine if the magnitude of LDL-C-lowering
differs by ethnicity.
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